Greco Michael N, Hawkins Michael J, Powell Eugene T, Almond Harold R, de Garavilla Lawrence, Hall Jeffrey, Minor Lisa K, Wang Yuanping, Corcoran Thomas W, Di Cera Enrico, Cantwell Angelene M, Savvides Savvas N, Damiano Bruce P, Maryanoff Bruce E
Research and Early Development, Johnson & Johnson Pharmaceutical Research and Development, Spring House, Pennsylvania 19477-0776, USA.
J Med Chem. 2007 Apr 19;50(8):1727-30. doi: 10.1021/jm0700619. Epub 2007 Mar 16.
A series of beta-carboxamido-phosphon(in)ic acids (2) was identified as a new structural motif for obtaining potent inhibitors of human mast cell chymase. For example, 1-naphthyl derivative 5f had an IC50 value of 29 nM and (E)-styryl derivative 6g had an IC50 value of 3.5 nM. An X-ray structure for 5f.chymase revealed key interactions within the enzyme active site. Compound 5f was selective for inhibiting chymase versus eight serine proteases. Compound 6h was orally bioavailable in rats (F=39%), and orally efficacious in a hamster model of inflammation.
